Physician profile
Matthew Schmitt
NPI 1144558545
$31,956.41
in general payments reported to CMS, 2019-2025
42 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $268 · 2021: $150 · 2022: $1,413 · 2023: $7,810 · 2024: $11K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Education: $9,805 · Food and Beverage: $2,837 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,221.41 |
| Education | $9,804.99 |
| Food and Beverage | $2,837.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $27,995.04 | 2022-2025 | Watchpatone |
| Jazz Pharmaceuticals INC. | $724.20 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $375.87 | 2023-2025 | Lumryz |
| Inspire Medical Systems, INC. | $257.21 | 2023-2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $249.63 | 2022-2025 | Quviviq, Quviviq |
| Grifols USA, LLC | $226.73 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Zoll Respicardia, INC. | $165.53 | 2024 | Remede System |
| Harmony Biosciences LLC | $164.60 | 2020-2023 | Wakix |
| Pfizer INC. | $152.88 | 2019-2023 | |
| Axsome Therapeutics, INC. | $151.64 | 2022-2025 | Sunosi |
| Philips North America LLC | $127.39 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Astrazeneca Pharmaceuticals LP | $107.48 | 2019-2025 | Tezspire, Fasenra |
| Genzyme Corporation | $101.48 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $99.86 | 2023-2025 | Horizant, Edarbyclor |
| Insmed, INC. | $84.54 | 2025 | Brinsupri, Arikayce |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Schmitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.